Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

Vidhya Sreekumar; Dayanidhi Meher; Siddhartha Goutam; Manas Ranjan Mishra; Ratikanta Tripathy; Jyotirmoyee Jena

doi:10.5455/njppp.2021.11.01006202112012021

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 29 Jan 2021

Natl J Physiol Pharm Pharmacol. 2021; 11(5): 514-518

doi: 10.5455/njppp.2021.11.01006202112012021

Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

Vidhya Sreekumar, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, Jyotirmoyee Jena.

Cited By:1

Abstract
Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit. The introduction of dual peroxisome proliferator-activated receptors agonist has provided a new insight into the management of both diabetes and dyslipidemia.

Aim and Objective: Hence, this study aimed to compare the effect of saroglitazar and pioglitazone on the lipid parameters and glycemic profile in patients of diabetes mellitus with dyslipidemia.

Materials and Methods: Adult patients with diabetic mellitus with dyslipidemia fulfilling the inclusion criteria were included in the study. One group received saroglitazar (4 mg/day) and the other group received pioglitazone (15 mg/day). Lipid parameters; triglyceride (TG), low-density lipoprotein, high-density lipoprotein (HDL), and serum cholesterol levels and glycemic parameters; fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycosylated hemoglobin (HbA1C) were measured at baseline and month 3, 6, and 12.

Results: Significant improvement seen in TG and HDL level at month 12 from baseline in both the treatment groups but saroglitazar was more effective than pioglitazone (P < 0.05). FPG, PPPG, and HbA1C were also reduced significantly from the baseline at the end of the study period (P < 0.05). Both the drugs were not associated with any sever adverse drug reactions.

Conclusion: The current study showed that saroglitazar was more effective than pioglitazone in controlling lipid and glycemic parameters in diabetic patients with dyslipidemia.

Key words: Diabetes Mellitus; Glycemic Parameters; Dyslipidemia

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Vidhya Sreekumar Articles by Dayanidhi Meher Articles by Siddhartha Goutam Articles by Manas Ranjan Mishra Articles by Ratikanta Tripathy Articles by Jyotirmoyee Jena
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. 2021; 11(5): 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

Web Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. https://www.njppp.com/?mno=38973 [Access: June 27, 2026].

doi:10.5455/njppp.2021.11.01006202112012021

AMA (American Medical Association) Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. 2021; 11(5): 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

Vancouver/ICMJE Style

Sreekumar V, Meher D, Goutam S, Mishra MR, Tripathy R, Jena J. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol. (2021), [cited June 27, 2026]; 11(5): 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

Harvard Style

Sreekumar, V., Meher, . D., Goutam, . S., Mishra, . M. R., Tripathy, . R. & Jena, . J. (2021) Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. Natl J Physiol Pharm Pharmacol, 11 (5), 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

Turabian Style

Sreekumar, Vidhya, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, and Jyotirmoyee Jena. 2021. Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (5), 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

Chicago Style

Sreekumar, Vidhya, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, and Jyotirmoyee Jena. "Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 514-518.

doi:10.5455/njppp.2021.11.01006202112012021

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2021.11.01006202112012021

APA (American Psychological Association) Style

doi:10.5455/njppp.2021.11.01006202112012021

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article